Creative Medical Technology Holdings Inc (CELZ) - Total Liabilities
Based on the latest financial reports, Creative Medical Technology Holdings Inc (CELZ) has total liabilities worth $261.35K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Creative Medical Technology Holdings Inc operating cash flow efficiency to assess how effectively this company generates cash.
Creative Medical Technology Holdings Inc - Total Liabilities Trend (2006–2024)
This chart illustrates how Creative Medical Technology Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. Check CELZ financial resilience to evaluate the company's liquid asset resilience ratio.
Creative Medical Technology Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Creative Medical Technology Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Watta Holding Bhd
KLSE:7226
|
Malaysia | RM11.71 Million |
|
Kerlink SAS
PA:ALKLK
|
France | €16.21 Million |
|
Processa Pharmaceuticals Inc
NASDAQ:PCSA
|
USA | $2.24 Million |
|
Box Pak (Malaysia) Bhd
KLSE:6297
|
Malaysia | RM375.01 Million |
|
Openn Negotiation Ltd
AU:OPN
|
Australia | AU$131.18K |
|
SMIS Corporation Bhd
KLSE:7132
|
Malaysia | RM37.69 Million |
|
Purple Biotech
NASDAQ:PPBT
|
USA | $6.25 Million |
Liability Composition Analysis (2006–2024)
This chart breaks down Creative Medical Technology Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Creative Medical Technology Holdings Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 20.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Creative Medical Technology Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Creative Medical Technology Holdings Inc (2006–2024)
The table below shows the annual total liabilities of Creative Medical Technology Holdings Inc from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $327.64K | -11.78% |
| 2023-12-31 | $371.39K | -88.82% |
| 2022-12-31 | $3.32 Million | +216.21% |
| 2021-12-31 | $1.05 Million | -97.41% |
| 2020-12-31 | $40.52 Million | +371.05% |
| 2019-12-31 | $8.60 Million | +92.37% |
| 2018-12-31 | $4.47 Million | +83.32% |
| 2017-12-31 | $2.44 Million | +407.87% |
| 2016-12-31 | $480.30K | +161.01% |
| 2015-12-31 | $184.02K | +19.50% |
| 2014-12-31 | $154.00K | +22.80% |
| 2013-12-31 | $125.41K | +26.27% |
| 2012-12-31 | $99.32K | +31.95% |
| 2011-12-31 | $75.27K | +55.12% |
| 2010-12-31 | $48.52K | +43.02% |
| 2009-12-31 | $33.93K | +4454.09% |
| 2008-12-31 | $745.00 | -91.97% |
| 2007-12-31 | $9.28K | +9.90% |
| 2006-12-31 | $8.45K | -- |
About Creative Medical Technology Holdings Inc
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DD… Read more